IPMA-PLUS Tablets

(Iron Polymaltose Complex + Folic Acid)

ایپما۔پلس ٹیبلیٹس

(آئرن پولی مالٹوز کمپلیکس+فولک ایسڈ)

Composition:
Each chewable tablet:
Contains Iron Polymaltose Complex equivalent to
Elemental Iron.....100mg
Folic Acid.....0.35mg

Description:
Iron (III) hydroxide Polymaltose Complex is a water soluble iron oxide, macro-molecular complex of poly-nuclear iron (III) hydroxide and partially hydrolyzed dextrin (Polymaltose).
The polynuclear iron (III) hydroxide cores are superficially surrounded by a number of non-covalently bonded, polymaltose molecules resulting in an overall complex molecular mass of approximately 52800 Daltons. This molecule is so large that diffusion through mucosal membrane is about 40 times smaller than that of hexaquo-iron (II) unity. The complex is stable and does not release ionic iron under physiological conditions. The iron in polynuclear "cores" is bound in a similar structure as in the case of physiologically occurring ferritin. Iron in **IPMA PLUS** chewable tablets exists as iron (III) hydroxide complex, where individual particles are embedded into a carbohydrate polymer (Polymaltose). This prevents the iron from causing any harm'in gastrointestinal system. This protection inhibits interactions of the iron with food.
As Iron (III) hydroxide Polymaltose Complex is similar to ferritin, the naturally occuring iron storage protein, due to this similarity, iron is absorbed through natural mechanisms. Due to these chemical and pharmaceolgical properties, **IPMA PLUS** chewable tablets are suitable for oral iron substitution.

Indications:
IPMA PLUS chewable tablets are indicated for prevention of all kinds of iron deficiency anemia. Tablet formulation is especially for the prophylactic therapy of iron deficiency to cover the Recommended Daily-dietary Allowances **(RDA)** during pregnancy and lactation, adolescents, women capable of bearing children and adults.

Dosage and Administration:
Dosage and duration of **IPMA PLUS** chewable tablets therapy are dependent upon the extent of iron deficiency. Daily dosage can be divided into separate doses or can be taken at one time. **IPMA PLUS** chewable tablets can be chewed or swallowed whole and should be taken during or immediately after meal.

Age Group	Formulation	Manifested Deficiency	Latent Deficiency
Pregnant and Nursing Woman	IPMA PLUS Chewable Tablets	1-3 Tablets Daily	1 Tablet Daily

Duration of Treatment:
In case of manifested iron deficiency, the **IPMA PLUS** chewable tablets therapy takes about 3-5 months until a normalization of the Haemoglobin value is achieved. Afterwards the therapy should be continued for several weeks with dosage such as described for latent iron deficiency to replenish the iron stores.

Contraindications:
Iron overload e.g. haemochromatosis, haemosiderosis.
Disturbed Iron utilization e.g. lead anemia, sidero-achrestic anemia, thalassemia.
Anemia not caused by iron deficiency e.g. haemolytic anemia.

Warnings and Precautions:
In case of anemia due to infections or malignancy, the substituted iron is stored in the reticulo-endothelial system, from which it is mobilized and utilized only after curing the primary disease.

Interactions:
Until now interactions have not been observed. Since the iron is complex bond, ionic interactions with food stuff components (phytin, oxalates, tannin etc.) and concomitant administration of medicament (tetracycline, antacids) are unlikely to occur. **IPMA PLUS** chewable tablets don't cause teeth staining. The haemoccult-test (selective for haemoglobin) for the detection of occult blood is not impaired and therefore iron therapy must not be interrupted.

Pregnancy & Lactation:
Reproduction studies in animals did not show any fetal risk. Controlled studies in pregnant women after the first trimester have not shown any undesirable effects on mother and neonates. There is no evidence of any risk during the first trimester and the possibility of a negative influence on the fetus is unlikely to occur. Mother's milk contains iron bond to lactoferrin. It is not known how much iron from the complex passed into mother's milk. The administration of **IPMA PLUS** chewable tablets is unlikely to cause undesirable effects to the nursed child. During pregnancy and lactation **IPMA PLUS** chewable tablets should be used on prescription.

Undesirable Effects:
Occasionally gastrointestinal irritation such as sensation of repletion, pressure in epi-gastric region, nausea, constipation or diarrhoea can occur. A dark coloration of the stool is of no clinical significance.

Overdose:
In case of over dosage of **IPMA PLUS** chewable tablets neither intoxication nor iron overload have been Reported up-to-date.

Instructions:
Use as directed by the physician. Protect from heat, sunlight and moisture. Store below 30°C. Keep all medicines out of the reach of children.

Presentation:
Each Pack of **IPMA PLUS** chewable tablets contains three blisters of 10 Tablets.
Each Pack of **IPMA PLUS** chewable tablets contains one blister of 10 Tablets.

خوراک: ڈاکٹر کی ہدایت کے مطابق استعمال کریں۔
ہدایات: دوا کو دھوپ، گرمی اور نمی سے بچائیں۔
۳۰ ڈگری سینٹی گریڈ سے کم درجہ حرارت پر رکھیں۔
تمام ادویات بچوں کی پہنچ سے دور رکھیں۔

Manufactured by:
Vega Pharmaceuticals (Pvt.) Ltd.
Pharma City Plot No 4, 30-km, Multan Road, Lahore